-
公开(公告)号：US07217517B2
公开(公告)日：2007-05-15
申请号：US10277969
申请日：2002-10-23
申请人： John E. Thompson , Catherine Taylor , Dominic Cliche , Charles Dinarello , Leonid Reznikov , Benjamin Pomerantz
发明人： John E. Thompson , Catherine Taylor , Dominic Cliche , Charles Dinarello , Leonid Reznikov , Benjamin Pomerantz
CPC分类号： C07K14/4747 , C12Q1/6883 , C12Q2600/158
摘要： The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.
摘要翻译： 本发明提供了确定哺乳动物组织，特别是哺乳动物心脏组织中缺血发生率的方法。 此外，提供了减少哺乳动物组织，优选心脏组织中细胞凋亡的方法。 这些方法包括测量和比较凋亡特异性eIF-5A和增殖eIF-5A两者的基因表达水平，并且当凋亡特异性eIF-5a的表达水平高于增殖eIF-5A时，相关缺血发生率。 在减少哺乳动物组织中凋亡的方法中，提供了抑制细胞凋亡特异性eIF-5A表达的药物。 优选的试剂是对人细胞凋亡特异性eIF-5A的反义寡核苷酸。
-
">
2.发明申请Inhibition of Apoptosis-Specific eIF-5A(elF-5A1") with Antisense Oligonucleotides and siRNA as Anti-Inflammatory Therapeutics 失效具有反义寡核苷酸和siRNA作为抗炎治疗剂的细胞凋亡特异性eIF-5A（“elF-5A1”）的抑制公开(公告)号：US20120129910A1
公开(公告)日：2012-05-24
申请号：US13099171
申请日：2011-05-02
申请人： John E. Thompson , Bruce C. Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
发明人： John E. Thompson , Bruce C. Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
IPC分类号： A61K31/713 , C12N5/071 , C07H21/02
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.
摘要翻译： 本发明涉及凋亡特异性真核起始因子5A（eIF-5A），被称为凋亡特异性eIF-5A或eIF5A1，核酸和多肽，以及使用反义核苷酸或siRNA抑制或抑制细胞凋亡以抑制表达的方法 的凋亡特异性eIF-5A。 本发明还涉及通过抑制细胞凋亡特异性eIF-5A的表达来抑制或抑制促炎细胞因子的表达或抑制NFkB的活化。
-
3.发明授权Inhibition of apoptosis-specific eIF-5A(eIF-5A1″) with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics 失效用反义寡核苷酸和siRNA作为抗炎治疗剂抑制凋亡特异性eIF-5A（“eIF-5A1”）公开(公告)号：US08754057B2
公开(公告)日：2014-06-17
申请号：US13099171
申请日：2011-05-02
申请人： John E. Thompson , Bruce C. Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
发明人： John E. Thompson , Bruce C. Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
IPC分类号： C12N15/11 , C12N15/113
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.
摘要翻译： 本发明涉及凋亡特异性真核起始因子5A（eIF-5A），称为凋亡特异性eIF-5A或eIF5A1，核酸和多肽，以及使用反义核苷酸或siRNA抑制或抑制细胞凋亡以抑制表达的方法 的凋亡特异性eIF-5A。 本发明还涉及通过抑制细胞凋亡特异性eIF-5A的表达来抑制或抑制促炎细胞因子的表达或抑制NFkB的活化。
-
">
4.发明申请Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics 审中-公开用反义寡核苷酸和siRNA作为抗炎治疗剂抑制凋亡特异性eIF-5A（“eIF-5A1”）公开(公告)号：US20060094677A1
公开(公告)日：2006-05-04
申请号：US11134445
申请日：2005-05-23
申请人： John Thompson , Bruce Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
发明人： John Thompson , Bruce Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFKB by inhibiting expression of apoptosis-specific eIF-5A.
摘要翻译： 本发明涉及凋亡特异性真核起始因子5A（eIF-5A），称为凋亡特异性eIF-5A或eIF5A1，核酸和多肽，以及使用反义核苷酸或siRNA抑制或抑制细胞凋亡以抑制表达的方法 的凋亡特异性eIF-5A。 本发明还涉及通过抑制凋亡特异性eIF-5A的表达来抑制或抑制促炎细胞因子的表达或抑制NFκB的活化。
-
">
5.发明申请Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics 审中-公开用反义寡核苷酸和siRNA作为抗炎治疗剂抑制凋亡特异性eIF-5A（“eIF-5A1”）公开(公告)号：US20100168047A9
公开(公告)日：2010-07-01
申请号：US11134445
申请日：2005-05-23
申请人： John Thompson , Bruce Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
发明人： John Thompson , Bruce Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFKB by inhibiting expression of apoptosis-specific eIF-5A.
摘要翻译： 本发明涉及凋亡特异性真核起始因子5A（eIF-5A），称为凋亡特异性eIF-5A或eIF5A1，核酸和多肽，以及使用反义核苷酸或siRNA抑制或抑制细胞凋亡以抑制表达的方法 的凋亡特异性eIF-5A。 本发明还涉及通过抑制凋亡特异性eIF-5A的表达来抑制或抑制促炎细胞因子的表达或抑制NFκB的活化。
-
公开(公告)号：US20060287265A1
公开(公告)日：2006-12-21
申请号：US11293391
申请日：2005-12-05
申请人： John Thompson , Bruce Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
发明人： John Thompson , Bruce Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
CPC分类号： C07K14/4747 , A61K48/00
摘要： The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for increasing or decreasing expression of apoptosis-specific eIF-5A. The invention also relates to methods of increasing or decreasing apoptosis.
摘要翻译： 本发明涉及凋亡特异性真核起始因子5A（eIF-5A），称为凋亡特异性eIF-5A或eIF5-A1核酸和多肽，以及用于增加或减少凋亡特异性eIF-5A表达的方法。 本发明还涉及增加或减少凋亡的方法。
-
7.发明申请Use of apoptosis-specific eIF-5A siRNAs and antisense polynucleotides to inhibit/suppress an inflammatory response 审中-公开使用凋亡特异性eIF-5A siRNA和反义多核苷酸抑制/抑制炎性反应公开(公告)号：US20060154887A1
公开(公告)日：2006-07-13
申请号：US11184982
申请日：2005-07-20
申请人： John Thompson , Bruce Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
发明人： John Thompson , Bruce Galton , Catherine Taylor , Charles Dinarello , Leonid Reznikov , Adrienne Boone , Marianne Hopkins
CPC分类号： C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.
摘要翻译： 本发明涉及凋亡特异性真核起始因子5A（eIF-5A），被称为凋亡特异性eIF-5A或eIF5-A1核酸和多肽，以及使用反义核苷酸或siRNA对细胞凋亡抑制或抑制凋亡的方法 抑制凋亡特异性eIF-5A的表达。 本发明还涉及通过抑制细胞凋亡特异性eIF-5A的表达来抑制或抑制促炎细胞因子的表达或抑制NFkB的活化。
-
8.发明申请Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis 有权白细胞介素-18结合蛋白，其制备和用于治疗败血症公开(公告)号：US20070081975A1
公开(公告)日：2007-04-12
申请号：US11505554
申请日：2006-08-16
申请人： Daniela Novick , Charles Dinarello , Menachem Rubinstein , Soo Kim , Giamila Fantuzzi , Leonid Reznikov , Boris Schwartsburd
发明人： Daniela Novick , Charles Dinarello , Menachem Rubinstein , Soo Kim , Giamila Fantuzzi , Leonid Reznikov , Boris Schwartsburd
CPC分类号： A61K38/1793 , A61K38/00 , A61K38/21 , A61K39/395 , A61K39/3955 , A61K48/00 , A61K2039/505 , C07K14/7155 , C07K16/18 , C07K16/244 , C07K16/2866 , C07K2319/00 , A61K2300/00
摘要： The present invention provides a method of treatment or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock, and sepsis related to cardiac dysfunction.
摘要翻译： 本发明提供一种治疗或预防脓毒病和其他系统性炎症反应综合征（SIRS）特征的疾病的方法，包括严重败血症，败血性休克和与心脏功能障碍有关的败血症。
-
公开(公告)号：US20070238691A1
公开(公告)日：2007-10-11
申请号：US11727748
申请日：2007-03-28
IPC分类号： A61K48/00
CPC分类号： C12N15/1137 , C12N15/1132 , C12N2310/11 , C12N2310/14 , C12N2740/16211
摘要： The present invention relates to methods of inhibiting the replication of the HIV virus by providing siRNA or antisense polynucleotides of eIF-5A1. The present invention also provides methods of inhibiting expression of p24 with siRNA or antisense polynucleotides of eIF-5A1.
摘要翻译： 本发明涉及通过提供eIF-5A1的siRNA或反义多核苷酸来抑制HIV病毒复制的方法。 本发明还提供了用eIF-5A1的siRNA或反义多核苷酸抑制p24表达的方法。
-
10.发明授权Compositions and methods for preparing a subject for organ or non-organ implantation 有权用于器官或非器官植入的制剂的组合物和方法公开(公告)号：US09486509B2
公开(公告)日：2016-11-08
申请号：US14227414
申请日：2014-03-27
申请人： Peter Gottlieb , Charles Dinarello
发明人： Peter Gottlieb , Charles Dinarello
CPC分类号： C07K14/8125 , A61K38/57 , A61K39/001 , A61K39/395 , A61K45/06 , A61K2039/505 , A61K2039/545 , A61K2039/55 , A61K2039/577 , C07K16/00 , C07K19/00 , C07K2319/00
摘要： Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantion rejection in the subject. Other embodiments include treating a subject with a composition including AAT before, during or after plastic surgery.
摘要翻译： 本发明的实施方案说明了防止移植排斥的方法。 在某些实施方案中，需要器官移植或非器官移植的受试者可以用AAT组合物进行预处理，以减少受试者的移植排斥发生率。 其他实施方案包括在整形手术之前，期间或之后用包含AAT的组合物治疗受试者。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.03 秒)
